Hu KQ, Cui W, Rouster SD, Sherman KE. Hepatitis C virus antigens enzyme immunoassay for one-step diagnosis of hepatitis C virus coinfection in human immunodeficiency virus infected individuals. World J Hepatol 2019; 11(5): 442-449 [PMID: 31183004 DOI: 10.4254/wjh.v11.i5.442]
Corresponding Author of This Article
Ke-Qin Hu, MD, FAASLD, Division of GI/Hepatology, University of California, Irvine, School of Medicine, 101 The City Drive, Building 56, Ste. 801, Orange, CA 92868, United States. kqhu@uci.edu
Research Domain of This Article
Methodology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. May 27, 2019; 11(5): 442-449 Published online May 27, 2019. doi: 10.4254/wjh.v11.i5.442
Hepatitis C virus antigens enzyme immunoassay for one-step diagnosis of hepatitis C virus coinfection in human immunodeficiency virus infected individuals
Ke-Qin Hu, Wei Cui, Susan D Rouster, Kenneth E Sherman
Ke-Qin Hu, Wei Cui, Division of GI/Hepatology, University of California, Irvine, School of Medicine, Orange, CA 92868, United States
Susan D Rouster, Kenneth E Sherman, Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, United States
Author contributions: Hu KQ contributed to the study design, data collection and analysis, and writing and editing of the manuscript; Cui W contributed to experiment performance, data collection and analysis, and preparing the manuscript; Rouster S and Sherman K contributed to serum samples, data analysis, and preparing the manuscript.
Institutional review board statement: This research project has been approved by the University of California, Irvine, and University of Cincinnati College of Medicine Institutional Review Board.
Conflict-of-interest statement: All authors have no conflicts of interest related to this study.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ke-Qin Hu, MD, FAASLD, Division of GI/Hepatology, University of California, Irvine, School of Medicine, 101 The City Drive, Building 56, Ste. 801, Orange, CA 92868, United States. kqhu@uci.edu
Telephone: +1-714-4566926 Fax: +1-714-4563283
Received: January 14, 2019 Peer-review started: February 13, 2019 First decision: March 8, 2019 Revised: May 8, 2019 Accepted: May 21, 2019 Article in press: May 21, 2019 Published online: May 27, 2019 Processing time: 103 Days and 3.9 Hours
ARTICLE HIGHLIGHTS
Research background
Current diagnosis of hepatitis C virus (HCV) infection requires two sequential steps: testing for anti-HCV followed by HCV RNA PCR to confirm viremic infection. We have developed a highly sensitive and specific HCV-antigens (Ags) enzyme immunoassay (EIA) for one-step diagnosis of viremic HCV infection. However, it has not been tested blindly and especially in those with HCV and human immunodeficiency virus (HIV) coinfection.
Research motivation
Although HCV RNA RT-PCR tests are highly sensitive and specific for viremic HCV infection, it is time consuming, costly, and not available and affordable in many developing countries and regions. Further confirming the sensitivity and specificity of HCV-Ags EIA will provide additional support of its clinical value for one-step screening and diagnosing HCV viremic infection.
Research objectives
The present study was aimed to blindly assess the clinical application of the HCV-Ags EIA in one-step diagnosis of viremic HCV infection in HCV-infected and HCV/HIV-coinfected individuals.
Research methods
The study blindly tested HCV-Ags EIA for its performance in one-step diagnosing viremic HCV infection in 147 sera, 10 without HCV or HIV infection; 54 with viremic HCV monoinfection; 38 with viremic HCV/HIV coinfection; and 45 with viremic HCV and non-viremic HIV coinfection.
Research results
The modified HCV-Ags EIA has a lower detection limit equivalent to serum HCV RNA levels of approximately 100 IU/mL. It is highly sensitive and specific in the setting of HIV coinfection, regardless of HIV infection status and CD4 count.
Research conclusions
These data support the clinical application of the HCV-Ags test in one-step diagnosis of HCV infection in HIV-infected individuals.
Research perspectives
The HCV-Ags EIA will be a novel addition to the current standard and is a more cost-effective one-step HCV screening and diagnosis method.
